New registry to track COVID-19 drug safety in pregnancy
NCT ID NCT05013632
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 25 times
Summary
This study follows 2,000 pregnant women who received monoclonal antibodies or antiviral drugs for COVID-19, along with a comparison group. Researchers will track pregnancy outcomes, newborn health, and infant development up to 12 months. The goal is to understand the safety and effects of these treatments during pregnancy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pregistry
RECRUITINGLos Angeles, California, 90045, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.